eli lilly tirzepatide compound Compounders protest as FDA removes off shortage list US judge denies injunction, restricting

CEO Rob Fried reveals Niagen Biosciences NAD+ growth strategy, from Tru Niagen to their upcoming telehealth launch

These results are not only statistically significant but also clinically meaningful, as weight reductions of this scale can lead to substantial improvements in health outcomes related to obesity, including reductions in risk factors for cardiovascular diseases and diabetes

Despite warnings about the potential risks of mixing alcohol and Semaglutide, Michael continued his usual drinking habits

The powder is third-party certified, so you can trust what's on the label

Key TakeawaysGLP-1 drugs might lower the risk of dangerous blood clots and death among people with autoimmune diseasesPeople taking GLP-1 drugs were 44% less likely to dieThey also had a lower risk of blood clots in their lungs or causing a stroke.WEDNESDAY, June 17, 2026 (HealthDay News) People with an autoimmune disease and obesity might lower their risk of dangerous blood clots and death by taking Ozempic or Zepbound, a new study says.Autoimmune diseases like celiac disease, vitiligo, psoriasis or rheumatoid arthritis increase the risk of severe heath emergencies because they cause inflammation and malfunctioning immune responses, researchers said.But GLP-1 medications might be able to counter that risk, researchers reported recently in the Journal of the American Heart Association.Overall, peoples risk of death was cut by nearly half if they were taking a GLP-1 drug, the study found.In this real-world analysis, we found a consistent signal toward fewer serious complications including blood clots and lower mortality among patients treated with GLP-1 receptor agonists, senior researcher Dr